UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 29, 2019
| CORBUS PHARMACEUTICALS HOLDINGS, INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware | 001-37348 | 46-4348039 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 500 River Ridge Drive, Norwood, MA | 02062 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617) 963-0100
| Not Applicable |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item 1.02 Termination of Material Definitive Agreement.
On January 29, 2019, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) provided notice of its termination of the Controlled Equity OfferingSM Sales Agreement, dated as of January 5, 2018 (the “Sales Agreement”), by and between the Company and Cantor Fitzgerald & Co. (the “Agent”). The termination of the Sales Agreement will be effective on February 8, 2019. As previously reported, pursuant to the terms of the Sales Agreement, the Company could offer and sell shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50 million from time to time through the Agent. Since January 5, 2018, the Company has sold 1,500,000 shares of its Common Stock pursuant to the Sales Agreement for aggregate gross proceeds of approximately $11.7 million. The Company does not intend to affect any further sales under the Sales Agreement prior to its termination.
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | ||
| Dated: January 30, 2019 | By: | /s/ Sean Moran |
| Name: | Sean Moran | |
| Title: | Chief Financial Officer | |
| -3- |